• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

A Digital Detox for the Soul with Lynch Syndrome

by MM360 Staff | Apr 25, 2025 | Uncategorized

Source: CureToday articles Unplugging from digital noise helped me find peace, clarity and room for growth during a season of emotional and mental renewal. Read More

Decipher Prostate Test Now Available for Metastatic Prostate Cancer

by MM360 Staff | Apr 25, 2025 | Uncategorized

Source: CureToday articles Decipher Prostate Metastatic Genomic Classifier is now available for patients with metastatic prostate cancer. Read More

Evorpacept With Keytruda Did Not Elicit Responses in Head and Neck Cancer

by MM360 Staff | Apr 25, 2025 | Uncategorized

Source: CureToday articles In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 and ASPEN trials. Read More

ctDNA Clearance Linked to Improved Survival in Oncogene-Driven NSCLC

by MM360 Staff | Apr 25, 2025 | Uncategorized

Source: CureToday articles Among patients with oncogene-driven advanced NSCLC who were treated with TKIs, ctDNA clearance was associated with improved survival end points. Read More

The Fearless Patient Advocate

by MM360 Staff | Apr 24, 2025 | Uncategorized

Source: CureToday articles Kathleen Coughlin, although small in stature, is often referred to as the “Bulldozer.” Read More

Working to Address Unmet Medical Needs in MPNs

by MM360 Staff | Apr 24, 2025 | Uncategorized

Source: CureToday articles CURE spoke with John Crispino, the director of the division of experimental hematology at St. Jude Children’s Research Hospital. Read More
« Older Entries
Next Entries »

Recent Content

  • FDA approves ziftomenib to treat some relapsed leukemia patients
  • (no title)
  • The challenge of non-transplant eligible, newly diagnosed multiple myeloma
  • Camera pill to find pancreatic cancer seeks breakthrough status
  • Camera pill to find pancreatic cancer seeks breakthrough status
  • Tinostamustine named orphan drug for treating malignant gliomas
  • New combination therapy approach may improve ovarian cancer care
  • FDA approves 1st treatment for high-risk smoldering myeloma
  • CAR T-cell therapy candidate yields lasting response in tough lymphoma
  • Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT